Feature | May 20, 2015

Botox Injections Help Prevent Atrial Fibrillation After Cardiac Surgery

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

botox, atrial fibrillation, cardiac surgery, HRS

May 20, 2015 — A study presented at Heart Rhythm 2015 found that botulinum toxin (botox) injections into epicardial fat pads during coronary artery bypass graft (CABG) surgery can be beneficial for the patient. The injection not only reduces the incidence of post-operative atrial fibrillation (AF), but also provides substantial AF suppression after one year.

Heart Rhythm 2015 is the Heart Rhythm Society’s 36th annual scientific sessions, May 13-16 in Boston.  

AF is the most common arrhythmia complicating cardiac surgery and occurs in approximately 30-40 percent of patients undergoing CABG surgery. CABG is the most common type of open-heart surgery in the United States and improves blood flow to the heart to treat people with coronary heart disease. Patients who develop AF after cardiac surgery are at an increased risk of stroke and congestive heart failure.

The prospective, double-blind study randomized 60 patients with a history of paroxysmal AF undergoing CABG to receive either botox injections or a saline placebo injection during surgery. Patients were followed for one year to assess maintenance of sinus rhythm using an implantable loop recorder. All patients in both groups had successful epicardial fat pad injections without complications and with minimal additional surgery time. 

The incidence of early postoperative AF within 30 days after surgery was two patients (7 percent) in the botox group compared to nine patients (30 percent) in the placebo group. Between the 30-day period and up to the 12-month follow-up examination, seven of the 30 patients in the placebo group (27 percent) had recurrent AF, while no patients in the botox group (0 percent) experienced recurrent AF. Further, there were no complications observed during the one year follow-up. 

“Currently, there are no therapies available to reduce AF after open heart surgery, so the study results are very promising and help fulfill an unmet need in cardiology care,” said lead author Evgeny Pokushalov, M.D., Ph.D., State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation. “Botox injections in the epicardial fat pads have the potential to become standard of care for patients undergoing open heart surgery and provide a new opportunity to reduce AF and associated complications.”

The lead authors call for a large, multi-center study to assess the safety and efficacy of botox injections in the epicardial fat pads for AF prevention and to further showcase the clinical benefit of this technique.

For more information: www.hrsonline.org

Related Content

Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery| May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery| May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery| May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery| May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery| May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
Overlay Init